Novus Therapeutics – Consensus Indicates Potential 105.9% Upside

Broker Ratings

Novus Therapeutics found using ticker (NVUS) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 43 and 27 with a mean TP of 35. Given that the stocks previous close was at 17 this would indicate that there is a potential upside of 105.9%. The 50 day moving average now sits at 20.7 and the 200 day moving average is 13.83. The market capitalisation for the company is $24m. You can visit the company’s website by visiting: http://novustherapeutics.com

Novus Therapeutics, a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics is headquartered in Irvine, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp